J&J's medical device sales fall short, cancer drugs seen growing
Recasts with focus on medical device sales miss, Adds investor call details in paragraphs 8-10 and 17, updates shares
By Patrick Wingrove and Bhanvi Satija
April 16 (Reuters) -Johnson & Johnson's JNJ.N first-quarter revenue missed Wall Street estimates for medical devices on Tuesday and sales of its blockbuster psoriasis drug Stelara came in lower than expected as the company prepares for its loss of exclusivity in the U.S.
J&J's large medical devices business reported $7.82 billion in sales for the quarter, boosted by strong demand for Abiomed heart pumps and devices used in wound closure surgeries.
That was still short of analysts' estimates of $7.88 billion. Two analysts pointed to a weakness in J&J's vision care products and surgical devices.
"China-related issues seemed to play a restraining role in both divisions' underperformance," said Stifel analyst Rick Wise.
J&J shares were down 1.3% at $145.71. Shares of other medical device makers Zimmer Biomet ZBH.N, Stryker SYK.N and Medtronic MDT.N were also down about 1%
Sales of Carvykti, a cell therapy cancer treatment that analysts expect to bring in $1.15 billion this year, was $157 million for the quarter, missing Wall Street estimates of $200 million.
Supply has been a constraint on Carvykti sales, Wolk said, but added that the company was working with the U.S. FDA to enable increased capacity at its plants in New Jersey and Belgium.
J&J has doubled its manufacturing capacity for cell processing since 2023, a company executive said on an investor call. The drugmaker expects sales of Carvykti to continue to grow this year, particularly in the second half, as it expands capacity.
Sales of cancer drug Darzalex jumped 19% to $2.69 billion, about in line with expectations. The multiple myeloma treatment is expected to bring in sales of more than $11 billion this year, according to analysts.
Stelara sales were flat at $2.45 billion, falling short of analysts' expectations of $2.6 billion, according to LSEG data.
J&J Chief Financial Officer Joe Wolk said Stelara revenue was flat because of contracting with healthcare providers and pharmacy benefit managers in anticipation of the drug's loss of exclusivity in the U.S. next year.
"We probably expect this year to be flattish, maybe a little bit up in the United States, as we prepare for some contracts to preserve volume, but maybe give a little bit on price for the longer term," Wolk said.
J&J has struck deals to delay U.S. launches of biosimilars, or close copies, of Stelara until 2025, after a key patent expired last year.
Analysts have said the delayed competition will make the drug a larger contributor for J&J's 2024 and 2025 revenue than previously anticipated.
Stelara biosimilars are expected to launch elsewhere later this year. J&J reached an agreement with Alvotech ALVO.O in February to launch its version in Japan, Canada and Europe this year. The Luxembourg-based drugmaker began selling the medicine in Canada last month under the name Jamteki and can launch in Japan in May.
'SIGNIFICANT FLEXIBILITY' FOR DEALS
J&J announced this month that it had agreed to buy Shockwave Medical SWAV.O for $13.1 billion to acquire its device that uses vibrations to break down calcium deposits in heart vessels.
Wolk said operational growth in medical devices this quarter - up 6.3% from the year-ago quarter - "probably speaks to why we were seeking to add to that portfolio with the potential acquisition of Shockwave."
CEO Joaquin Duato said the company was still in the market for deals or acquisitions. "We have significant flexibility to consider multiple types of transactions," he said on the investor call.
On an adjusted basis, J&J earned $2.71 per share in the first quarter, beating estimates 7 cents. It reported total revenue of $21.38 billion, shy of estimates of $21.40 billion.
J&J raised the low end of its 2024 forecast by 5 cents and now expects an adjusted profit of $10.60 to $10.75 per share.
It also increased its quarterly dividend by 4.2% to $1.24 per share.
Sales of J&J's top selling treatments https://reut.rs/3Q30NA2
Reporting by Bhanvi Satija and Mariam Sunny in Bengaluru and Patrick Wingrove in New York; Editing by Shounak Dasgupta and Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
